Full Press Release Details
Bioscience Announces $7.0 Million
Direct Offering Priced At-The-Market under Nasdaq Rules
DIEGO August 30, 2023 (GLOBE NEWSWIRE) - Dar Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation,
today announced that it has entered into a definitive agreement with an institutional investor and an investor affiliated with the licensor
of one of the company's early stage product candidates for the purchase and sale of 10,000,000 shares of the company's common
stock and warrants to purchase up to 10,000,000 shares of the company's common stock in a registered direct offering priced at-the-market
under Nasdaq rules. Each warrant is exercisable for one share of the company's common stock. The offering price was $0.70 per share
of common stock and accompanying warrant. The warrants will be exercisable beginning six months after issuance, have a term of five and
one-half years from the date of issuance and have an exercise price of $0.77 per share. The closing of the offering is expected to occur
on or about September 1, 2023, subject to the satisfaction of customary closing conditions.
aggregate gross proceeds to Dar from the offering at the closing are expected to be $7.0 million before deducting estimated offering
expenses payable by Dar . Dar intends to use the proceeds from the offering for general corporate purposes, which may
include clinical trials, research and development activities, general and administrative costs, and to meet working capital needs.
securities described above are being offered and sold by Dar pursuant to a "shelf" registration statement on Form
S-3 (File No. 333-254862), including a base prospectus, previously filed with the Securities and Exchange Commission, or the SEC, on
March 30, 2021, and declared effective by the SEC on April 7, 2021. Such securities may be offered only by means of a prospectus, including
a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and an accompanying base
prospectus relating to the securities will be filed with the SEC. Electronic copies of the prospectus supplement and the accompanying
base prospectus may be obtained, when available, by visiting the SEC's website at http://www.sec.gov.
press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor
shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
Bioscience is a biopharmaceutical company committed to advancing innovative products for women's health. The company's mission
is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women's health and
well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, vaginal health, reproductive health,
menopause, sexual health and fertility.
first FDA-approved product, XACIATO (clindamycin phosphate) vaginal gel, 2% is a lincosamide antibacterial indicated for the treatment
of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Dar 's
portfolio also includes potential first-in-category candidates in clinical development: Ovaprene , a novel, hormone-free monthly
intravaginal contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream
formulation of sildenafil to treat female sexual arousal disorder (FSAD) and/or female sexual interest/arousal disorder (FSIAD) utilizing
the active ingredient in Viagra ; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for menopausal
hormone therapy. To learn more about XACIATO, Dar 's full portfolio of women's health product candidates, and Dar 's
mission to deliver differentiated therapies for women, please visit www.darebioscience.com.
may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors
section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Dar
will use these channels to distribute material information about the company, and may also use social media to communicate important
information about the company, its finances, product and product candidates, clinical trials and other matters. The information Dar
posts on its investor relations website or through social media channels may be deemed to be material information. Dar encourages
investors, the media, and others interested in the company to review the information Dar posts in the Investors section of its
website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the
company may use to communicate information will be posted in the Investors section of Dar 's website.
cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements.
Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will,"
"estimate," "continue," "anticipate," "design," "intend," "expect,"
"could," "plan," "potential," "predict," "seek," "should," "would,"
"contemplate," "project," "target," "objective," or the negative version of these words
and similar expressions. In this press release, forward-looking statements include, but are not limited to, statements relating to relating
to the offering, the completion of the offering and the expected use of proceeds from the offering. Forward-looking statements involve
known and unknown risks, uncertainties and other factors that may cause Dar 's actual results, performance or achievements
to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in
this press release, including, without limitation, risk and uncertainties related to: the closing of the offering, Dar 's
ability to raise additional capital when and as needed to advance its product candidates, execute its business strategy and continue
as a going concern; and Dar 's ability to develop, obtain FDA or foreign regulatory approval for, and commercialize its
product candidates and to do so on communicated timelines. Dar 's forward-looking statements are based upon its current
expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly
qualified in their entirety by these cautionary statements. For a detailed description of Dar 's risks and uncertainties,
you are encouraged to review its documents filed with the SEC including Dar 's recent filings on Form 8-K, Form 10-K and
Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they
were made. Dar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after
the date on which they were made, except as required by law.
on behalf of Dar Bioscience, Inc.:
Roth / Julia Weilman
on behalf of Dar Bioscience, Inc.:
Dar Bioscience, Inc.